Anti-PD-L1 Antibodies with Optimized Binding Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents targeting PD-L1 for cancer treatment vary in effectiveness due to unclear optimal binding sites and affinities, limiting their tumor cell-specificity and immune response enhancement.
Innovation Solution
Development of anti-PD-L1 monoclonal antibodies and antigen-binding fragments with specific amino acid sequences and binding affinities, capable of inhibiting PD-L1 binding to PD-1, enhancing T-cell activation, and reversing immunosuppressive functions, including those with human framework regions and various antibody formats like IgG, bispecific, or multi-specific configurations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmaceutical agents bind to PD-L1 to block negative co-stimulatory signals, then T-cell response is enhanced, but tumor cell-specificity and treatment effectiveness vary due to unclear optimal binding sites and affinities
Solution Approach 1:
The patent applies parameter changes by systematically varying the binding affinity parameters of anti-PD-L1 antibodies. Different antibody variants with distinct KD values (ranging from high nM to low nM affinity) are developed to identify the optimal binding strength that maximizes T-cell activation while maintaining tumor cell specificity. This parameter optimization resolves the contradiction by establishing a quantitative relationship between binding affinity and therapeutic effectiveness.
Solution Approach 2:
The patent employs local quality by targeting specific epitopes or binding sites on the PD-L1 protein structure. Rather than generic PD-L1 binding, the invention identifies and develops antibodies that bind to particular regions of PD-L1 with enhanced specificity. This localized binding approach improves tumor cell-specificity while maintaining the ability to block the PD-1/PD-L1 interaction, thereby resolving the contradiction between reliability and manufacturing precision.
2Adaptability or versatility
If anti-PD-L1 antibodies are developed with various formats and sequences, then versatility in treatment approaches is improved, but complexity of antibody development and characterization increases
Solution Approach 1:
The patent applies universality by developing a platform of anti-PD-L1 antibodies with different formats (full-length IgG, Fab fragments, scFv) that all target the same PD-L1 antigen. This multi-format approach provides versatility in treatment strategies while using a unified molecular target. The common binding specificity across different antibody formats allows for simplified development protocols and characterization methods, thereby resolving the contradiction between adaptability and complexity.
Solution Approach 2:
The patent employs segmentation by dividing the antibody molecule into different functional formats (heavy chains, light chains, variable regions, constant regions) that can be independently optimized or combined. This segmentation allows for modular development of antibody variants with tailored properties for different therapeutic applications, reducing overall development complexity through standardized building blocks while maintaining treatment versatility.
Data Source
AI summary
The application provides the anti-PD-L1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.